<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33123760</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Vasculitis changes in COVID-19 survivors with persistent symptoms: an [<sup>18</sup>F]FDG-PET/CT study.</ArticleTitle><Pagination><StartPage>1460</StartPage><EndPage>1466</EndPage><MedlinePgn>1460-1466</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-020-05084-3</ELocationID><Abstract><AbstractText Label="PURPOSE">Several patients experience unexplained persistent symptoms after SARS-CoV-2 recovering. We aimed at evaluating if 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) was able to demonstrate a persistent inflammatory process.</AbstractText><AbstractText Label="METHODS">Recovered adult COVID-19 patients, who complained unexplained persisting symptoms for more than 30&#xa0;days during the follow-up visits, were invited to participate in the study. Patients fulfilling inclusion criteria were imaged by [<sup>18</sup>F]FDG positron emission tomography/computed tomography ([<sup>18</sup>F]FDG-PET/CT). Whole-body [<sup>18</sup>F]FDG-PET/CT, performed according to good clinical practice, was qualitatively (comparison with background/liver) and semi-quantitatively (target-to-blood pool ratio calculated as average SUVmax artery/average SUVmean inferior vena cava) analyzed. Negative follow-up [<sup>18</sup>F]FDG-PET/CT images of oncologic patients matched for age/sex served as controls. Mann-Whitney test was used to test differences between groups. SPSS version 26 was used for analyses.</AbstractText><AbstractText Label="RESULTS">Ten recovered SARS-CoV-2 patients (seven male and three females, median age 52&#xa0;years, range 46-80) with persisting symptoms were enrolled in the study. Common findings at visual analysis were increased [<sup>18</sup>F]FDG uptake in bone marrow and blood vessels (8/10 and 6/10 cases, respectively). [<sup>18</sup>F]FDG uptake in bone marrow did not differ between cases and controls (p&#x2009;=&#x2009;0.16). The total vascular score was similar in the two groups (p&#x2009;=&#x2009;0.95). The target-to-blood pool ratio resulted higher in recovered SARS-CoV-2 patients than in controls.</AbstractText><AbstractText Label="CONCLUSION">Although the total vascular score was similar in the two groups, the target-to-blood pool ratio was significantly higher in three vascular regions (thoracic aorta, right iliac artery, and femoral arteries) in the recovered COVID-19 cohort than in controls, suggesting that SARS-CoV-2 induces vascular inflammation, which may be responsible for persisting symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sollini</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2214-6492</Identifier><AffiliationInfo><Affiliation>Humanitas Clinical and Research Center - IRCCS, Via Alessandro Manzoni 56, I20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, I20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccarelli</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8617-4153</Identifier><AffiliationInfo><Affiliation>Humanitas Clinical and Research Center - IRCCS, Via Alessandro Manzoni 56, I20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cecconi</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4376-6538</Identifier><AffiliationInfo><Affiliation>Humanitas Clinical and Research Center - IRCCS, Via Alessandro Manzoni 56, I20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, I20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghemo</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0941-3226</Identifier><AffiliationInfo><Affiliation>Humanitas Clinical and Research Center - IRCCS, Via Alessandro Manzoni 56, I20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, I20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Humanitas Clinical and Research Center - IRCCS, Via Alessandro Manzoni 56, I20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, I20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelardi</LastName><ForeName>Fabrizia</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7120-333X</Identifier><AffiliationInfo><Affiliation>Humanitas Clinical and Research Center - IRCCS, Via Alessandro Manzoni 56, I20089 Rozzano, Milan, Italy. fabrizia.gelardi@cancercenter.humanitas.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, I20090 Pieve Emanuele, Milan, Italy. fabrizia.gelardi@cancercenter.humanitas.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiti</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5806-1856</Identifier><AffiliationInfo><Affiliation>Humanitas Clinical and Research Center - IRCCS, Via Alessandro Manzoni 56, I20089 Rozzano, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, I20090 Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014657" MajorTopicYN="Y">Vasculitis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vasculitis</Keyword><Keyword MajorTopicYN="N">[18F]FDG-PET/CT</Keyword></KeywordList><CoiStatement>Sollini, Ciccarelli, Morelli, Aghemo, and Gelardi had no conflicts of interest. Cecconi MC reports personal fees from Edwards Lifesciences, Directed Systems, and Cheetah Medical, outside the submitted work. Chiti received speaker honoraria from General Electric and Blue Earth Diagnostics, acted as scientific advisor for Blue Earth Diagnostics and Advanced Accelerator Applications, and benefited from an unconditional grant from Sanofi to Institution. All honoraria and grants are outside the scope of the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>30</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33123760</ArticleId><ArticleId IdType="pmc">PMC7595761</ArticleId><ArticleId IdType="doi">10.1007/s00259-020-05084-3</ArticleId><ArticleId IdType="pii">10.1007/s00259-020-05084-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med Wiley. 2020;288:192&#x2013;206. doi: 10.1111/joim.13091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13091</ArticleId><ArticleId IdType="pmc">PMC7267177</ArticleId><ArticleId IdType="pubmed">32348588</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:594&#x2013;602. doi: 10.1016/S2665-9913(20)30275-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30275-7</ArticleId><ArticleId IdType="pmc">PMC7442426</ArticleId><ArticleId IdType="pubmed">32864628</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. Children and adolescents. N Engl J Med. 2020;383:334&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA American Medical Association. 2020;324:603. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647&#x2013;658. doi: 10.2967/jnumed.112.112524.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.112.112524</ArticleId><ArticleId IdType="pubmed">23359660</ArticleId></ArticleIdList></Reference><Reference><Citation>Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014;42:328&#x2013;354. doi: 10.1007/s00259-014-2961-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-014-2961-x</ArticleId><ArticleId IdType="pmc">PMC4315529</ArticleId><ArticleId IdType="pubmed">25452219</ArticleId></ArticleIdList></Reference><Reference><Citation>Slart RHJA. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging Springer. 2018;45:1250&#x2013;1269. doi: 10.1007/s00259-018-3973-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-3973-8</ArticleId><ArticleId IdType="pmc">PMC5954002</ArticleId><ArticleId IdType="pubmed">29637252</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis Springer. 2020;50:499&#x2013;511. doi: 10.1007/s11239-020-02230-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02230-4</ArticleId><ArticleId IdType="pmc">PMC7373848</ArticleId><ArticleId IdType="pubmed">32700024</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis Nature Publishing Group. 2020;50:54&#x2013;67. doi: 10.1007/s11239-020-02134-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02134-3</ArticleId><ArticleId IdType="pmc">PMC7225095</ArticleId><ArticleId IdType="pubmed">32415579</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, L&#xfc;scher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J Eur Heart J. 2020;41:3038&#x2013;3044. doi: 10.1093/eurheartj/ehaa623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa623</ArticleId><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>